AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02207946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Trial: NCT01998659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drinking solution
Trial: NCT02304302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
Trial: NCT03803514
Drug: Recombinant EPO
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
Trial: NCT01516684
Drug: placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT01516684
Drug: fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01860690
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg / meter squer Intramuscular (IM) MTX.
Trial: NCT03310307
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU
Trial: NCT00371553
Drug: SU011248 (Sunitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04686058
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
RxNorm normalized name: Pethidine hydrochloride 50 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01362010
Drug: Topical Minocycline Foam FXFM244
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once a day.
Trial: NCT00990418
Drug: Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose administered daily for 84 days.
Trial: NCT02351427
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
Trial: NCT01702636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01848041
Drug: RVL-1201 Vehicle Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVL-1201 Vehicle Placebo
Trial: NCT00730067
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
Trial: NCT01966107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Trial: NCT00839176
Drug: RX-10100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
Trial: NCT00532779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01457352
Drug: SPARC0921
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01457352
Drug: Placebo0921
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03459391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
Trial: NCT04655339
Drug: Bilateral abdominal Lap-TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
Trial: NCT01887366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
Trial: NCT00727441
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV (Arm B), given orally (Arm C)
Trial: NCT00216073
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Trial: NCT00642889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01015456
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous, monthly, for 6 months
Trial: NCT02617485
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Trial: NCT02617485
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
Trial: NCT00395057
Drug: AGN 211745
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
Trial: NCT00395057
Drug: AGN 211745
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
Trial: NCT00395057
Drug: AGN 211745
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
Trial: NCT04917302
Drug: NMDAE plus AIFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
Trial: NCT04917302
Drug: NMDAE plus Placebo Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus placebo as a comparator
Trial: NCT01109056
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the study eye (or eyes) administered four times daily (QID)
Trial: NCT03486327
Drug: BR55
RxNorm normalized name: Band-Aid Ourtone BR55 Bandages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel targeted ultrasound contrast agent
Trial: NCT03347929
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 days treatment with Naproxen 500 mg twice daily
Trial: NCT03347929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days treatment with Placebo1 tablet twice daily
Trial: NCT02856282
Drug: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
Trial: NCT02074982
Drug: AIN457 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02845219
Drug: SNAC
RxNorm normalized name: Glucerna Snack Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily together with oral contraceptive.
Trial: NCT02845219
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily alone or together with oral semaglutide or SNAC.
Trial: NCT02248428
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg orally daily on days 1-28,repeated every 28 days
Trial: NCT02248428
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
Trial: NCT03940183
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo Comparator groups use placebo oral tablet for 24weeks
Trial: NCT03565367
Drug: Hyperpolarized Carbon C 13 Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03005873
Drug: TLC599 LD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose via intra-articular injection
Trial: NCT03005873
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose via intra-articular injection
Trial: NCT03005873
Drug: TLC599 HD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose via intra-articular injection
Trial: NCT00532675
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAN 5 mg and PAN 20 mg capsules
Trial: NCT04585009
Drug: GSK3923868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Trial: NCT04585009
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Trial: NCT02416167
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02416167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01473589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT03560518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (prefilled syringe, weekly IV administration)
Trial: NCT03140527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01128621
Drug: GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01128621
Drug: GSK1292263 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02685059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
Trial: NCT02685059
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
Trial: NCT00583713
Drug: BLI-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI-800 oral solution (two doses)
Trial: NCT00796445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM solution, a course of 13 injections administered over 27 months
Trial: NCT04036292
Drug: OC-01 (varenicline) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT04036292
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) nasal spray
Trial: NCT00579384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
Trial: NCT00628043
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of placebo once-weekly for 12 weeks
Trial: NCT02049580
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Trial: NCT01299272
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04571164
Drug: Placebo,extended-release microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
Trial: NCT01491737
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
Trial: NCT01491737
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
Trial: NCT01888978
Drug: Modified FOLFOX-6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01888978
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01888978
Drug: Tax-Iri
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06700382
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: different methods of treatment for capecitabine
Trial: NCT01281631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT00045942
Drug: PKC412
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Trial: NCT00214721
Drug: Experimental Peritoneal Dialysis Solution
RxNorm normalized name: DEXTROSE/PERITONEAL DIALYSIS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00303589
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00303589
Drug: beta-lactam
RxNorm normalized name: Beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg iv q8h
Trial: NCT00303589
Drug: beta-lactam
RxNorm normalized name: Beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg iv q8h
Trial: NCT00422084
Drug: Coartem® (artemether lumefantrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
Trial: NCT04406272
Drug: VB11
RxNorm normalized name: Valsartan and Bumetanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
Trial: NCT01414920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT00345332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected
Trial: NCT00001131
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
Trial: NCT00711516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
Trial: NCT00021073
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00021073
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02353143
Drug: MEN1112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
Trial: NCT00662532
Drug: Minocycline HCl
RxNorm normalized name: minocycline HCl
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
Trial: NCT00411580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01328444
Drug: GSK 573719 +GW642444 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg/ 25mcg
Trial: NCT01328444
Drug: GSK573719 + GW642444 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5mcg/25mcg
Trial: NCT01328444
Drug: GSK 573719 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5mcg
Trial: NCT02092207
Drug: KL7016 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, 150mg 3tab, bid
Trial: NCT02092207
Drug: KL7016 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, 150mg 3tab, bid
Trial: NCT02092207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, 150mg 3tab, bid
Trial: NCT01328444
Drug: GW642444 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mcg
Trial: NCT03746288
Drug: CAN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
Trial: NCT02700334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one per day before breakfast during 12 weeks.
Trial: NCT03340103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
Trial: NCT01381562
Drug: Drug: GSK2251052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Trial: NCT00274092
Drug: Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01630278
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
Trial: NCT01630278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
Trial: NCT01554696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01554696
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT02260570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill that contains no active ingredient
Trial: NCT02730793
Drug: Nasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (nasal saline twice per day)
Trial: NCT01067339
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, by mouth, once daily for six months
Trial: NCT03700515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive weekly infusions of saline
Trial: NCT03005184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous medication